Technical Analysis for ADAP - Adaptimmune Therapeutics plc

Grade Last Price % Change Price Change
grade F 4.94 2.07% 0.10
ADAP closed up 2.07 percent on Friday, February 15, 2019, on 49 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Earnings due: Feb 27

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical ADAP trend table...

Date Alert Name Type % Chg
Feb 15 20 DMA Support Bullish 0.00%
Feb 15 Hammer Candlestick Bullish 0.00%
Feb 15 Bollinger Band Squeeze Range Contraction 0.00%
Feb 14 Crossed Above 20 DMA Bullish 2.07%
Feb 14 Bollinger Band Squeeze Range Contraction 2.07%
Feb 14 NR7 Range Contraction 2.07%
Feb 13 Bearish Engulfing Bearish 2.49%
Feb 13 Fell Below 20 DMA Bearish 2.49%
Feb 13 Fell Below 50 DMA Bearish 2.49%
Feb 13 180 Bearish Setup Bearish Swing Setup 2.49%

Older signals for ADAP ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Medicine Biopharmaceutical Cancer Clinical Medicine Alpha Solid Tumors Immunotherapy Cancer Treatments Non Small Cell Lung Cancer Cancer Immunotherapy Ovarian Cancer Virotherapy Multiple Myeloma Melanoma Hematological Malignancies Adoptive Cell Transfer Tumors Of The Hematopoietic And Lymphoid Tissues Cancer Immunotherapy Products Esophageal Cancer Oncolytics Biotech Breast And Lung Cancer
Is ADAP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.625
52 Week Low 3.6
Average Volume 460,492
200-Day Moving Average 9.1154
50-Day Moving Average 5.0552
20-Day Moving Average 4.793
10-Day Moving Average 4.913
Average True Range 0.3835
ADX 9.25
+DI 19.297
-DI 20.791
Chandelier Exit (Long, 3 ATRs ) 4.8195
Chandelier Exit (Short, 3 ATRs ) 5.5105
Upper Bollinger Band 5.2449
Lower Bollinger Band 4.3411
Percent B (%b) 0.66
BandWidth 18.856666
MACD Line -0.0574
MACD Signal Line -0.0983
MACD Histogram 0.0408
Fundamentals Value
Market Cap 461.98 Million
Num Shares 93.5 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -4.99
Price-to-Sales 39.39
Price-to-Book 2.97
PEG Ratio 0.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.41
Resistance 3 (R3) 5.36 5.16 5.33
Resistance 2 (R2) 5.16 5.04 5.18 5.30
Resistance 1 (R1) 5.05 4.97 5.11 5.10 5.28
Pivot Point 4.85 4.85 4.88 4.87 4.85
Support 1 (S1) 4.74 4.73 4.80 4.79 4.60
Support 2 (S2) 4.54 4.66 4.56 4.58
Support 3 (S3) 4.43 4.54 4.55
Support 4 (S4) 4.48